BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Professor Boissier, Member of the Scientific Board of Neovacs SA, Presents at International Biomedical R&D Dating 2013


10/24/2013 11:44:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Paris, October 24 2013 – NEOVACS (Alternext Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, annonced that Marie-Christophe Boissier, M.D., Ph.D., was one of the nine inflammation specialists selected to present today during the 5th International Biomedical R&D Dating held today in Paris.

Prof. Boissier presented the latest research conducted by his academic reserach team, including works with Neovacs’ TNF-Kinoid in Rheumatoid Arthritis (RA), to representatives of the pharmaceutical industry and French academic research meeting on the topic of inflammation and inflammatory pathologies research.

« I am thrilled that inflammation research was selected as the main topic for this 5th edition of the International Biomedical R&D Dating. Inflammatory pathologies like RA and lupus are severe and debilitating diseases with unmet medical needs. We are seeking a new therapeutic arsenal in RA to counteract chronic inflammation and tissular distruction” concludes Prof. Boissier.

Neovacs is initiating a phase IIb clinical trial of TNF-Kinoid in Rheumatoid Arthritis on 140 patients. The primary objective of this international, multicentric study versus placebo is to demonstrate clinical efficacy of active immunotherapy with the Kinoid in this patient population. Results are expected by the end of 2014.

About International Biomedical R&D Dating

Organized by ARIIS (The Alliance for Research and Innovation in Health Industries) and AVIESAN (French National Alliance for Life and Health Sciences), the International Biomedical R&D Dating aims to develop partnerships between French academic research teams and international health manufacturers. It is organized under the Patronage of Ministries of Social Affairs and Health, Industrial Renewal and Higher Education and Research. The 5th edition of the International Biomedical R&D Dating 2013 was dedicated to inflammation and inflammatory diseases research. It was held at the Carrousel du Louvre in Paris on October 24th 2013 with R&D decision-makers from 30 health industries and 59 academic research teams. Morning sessions were dedicated to academic presentation followed by bilateral meetings between representatives of industry and public research.

About Neovacs

Neovacs is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that run until at least 2026) Neovacs is focusing its development efforts on two active immunotherapies: TNF-Kinoid is being developed for the treatment of TNF-mediated autoimmune diseases such as rheumatoid arthritis and Crohn’s disease, whereas IFNa-Kinoid is being developed for the indication of lupus. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES